Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa trial of rhPDGF-BB gel for second-degree burns
ChiCTR2200062576Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of becaplermin in burn injury (3 arms), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: Safety and tolerability. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
becaplermin
03
Conditions
burn injury
Beyond the preview
Go deeper on ChiCTR2200062576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062576.